Phase 2 Data Demonstrate Potential of Vergent Biosciences’ Tumor-Targeted Fluorescent Imaging Agent to Improve Success of Lung Cancer Surgeries

Windham Venture Partners
|
September 11, 2023
Explore More
No items found.